MXPA04007556A - Estimulacion de cpt-1 como medio para reducir peso. - Google Patents
Estimulacion de cpt-1 como medio para reducir peso.Info
- Publication number
- MXPA04007556A MXPA04007556A MXPA04007556A MXPA04007556A MXPA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A
- Authority
- MX
- Mexico
- Prior art keywords
- cpt
- agent
- administered
- fatty acid
- amount sufficient
- Prior art date
Links
- 230000000638 stimulation Effects 0.000 title abstract 2
- 101150073133 Cpt1a gene Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 abstract 2
- 230000003647 oxidation Effects 0.000 abstract 2
- 238000007254 oxidation reaction Methods 0.000 abstract 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 abstract 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004136 fatty acid synthesis Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pediatric Medicine (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35448002P | 2002-02-08 | 2002-02-08 | |
| PCT/US2003/003839 WO2003066043A1 (en) | 2002-02-08 | 2003-02-10 | Stimulation of cpt-1 as a means to reduce weight |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007556A true MXPA04007556A (es) | 2005-12-05 |
Family
ID=27734382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007556A MXPA04007556A (es) | 2002-02-08 | 2003-02-10 | Estimulacion de cpt-1 como medio para reducir peso. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20050143467A1 (https=) |
| EP (1) | EP1471906A4 (https=) |
| JP (2) | JP2005523270A (https=) |
| KR (1) | KR20040082417A (https=) |
| CN (1) | CN1313089C (https=) |
| AU (2) | AU2003215111A1 (https=) |
| BR (1) | BR0307421A (https=) |
| CA (1) | CA2474884A1 (https=) |
| EA (1) | EA007029B1 (https=) |
| IL (1) | IL163312A (https=) |
| MX (1) | MXPA04007556A (https=) |
| WO (1) | WO2003066043A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1471906A4 (en) * | 2002-02-08 | 2006-02-01 | Univ Johns Hopkins Med | STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT |
| EP2386551A1 (en) * | 2002-07-09 | 2011-11-16 | Fasgen Inc. | Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| US20080119548A1 (en) * | 2004-03-18 | 2008-05-22 | Ronnett Gabrielle V | Control Of Feeding Behavior By Changing Neuronal Energy Balance |
| CN101022792A (zh) * | 2004-05-26 | 2007-08-22 | 法斯根有限责任公司 | 新化合物、包含该化合物的药物组合物及该化合物的应用方法 |
| BRPI0610877A2 (pt) * | 2005-06-06 | 2010-08-03 | Hoffmann La Roche | compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos |
| WO2007014248A2 (en) * | 2005-07-26 | 2007-02-01 | Johns Hopkins University | Method of reducing food intake |
| ATE418603T1 (de) * | 2005-08-29 | 2009-01-15 | Hoffmann La Roche | Kristallstrukturen von carnitine palmitoyltransferase-2 (cpt-2) und deren verwendung |
| ES2405259B1 (es) * | 2011-11-25 | 2014-09-29 | Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) | Uso del enantiómero (+)-c75 para el tratamiento de la obesidad. |
| WO2013155528A2 (en) * | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US574639A (en) | 1897-01-05 | Gold-saving device | ||
| DE3026368A1 (de) * | 1980-07-11 | 1982-02-18 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion |
| US5981575A (en) * | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
| US5914326A (en) * | 1997-08-08 | 1999-06-22 | Ambi Inc. | Method for promoting weight and fat loss |
| AU5802499A (en) * | 1998-09-01 | 2000-03-21 | Amway Corporation | Diet composition and method of weight management |
| AU784495B2 (en) * | 1999-11-12 | 2006-04-13 | Johns Hopkins University School Of Medicine, The | Treating cancer by increasing intracellular malonyl coa levels |
| KR20030016228A (ko) * | 2000-02-16 | 2003-02-26 | 존스 홉킨스 유니버시티 스쿨 오브 메디슨 | 신경펩티드 ｙ 농도의 감소에 의해 유도되는 체중 감량 |
| WO2002079501A1 (en) * | 2001-03-30 | 2002-10-10 | Trustees Of Boston University | Methods and reagents for identifying weight loss promoters and therapeutic uses therefor |
| EP1471906A4 (en) * | 2002-02-08 | 2006-02-01 | Univ Johns Hopkins Med | STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT |
| US20040161803A1 (en) * | 2002-04-01 | 2004-08-19 | Corkey Barbara E. | Methods and reagents for identifying weight loss promoters and therpeutic uses therefor |
| EP1534263A4 (en) | 2002-07-01 | 2006-10-11 | Fasgen Llc | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF ADMINISTRATION THEREFOR |
| EP2386551A1 (en) | 2002-07-09 | 2011-11-16 | Fasgen Inc. | Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
-
2003
- 2003-02-10 EP EP03710928A patent/EP1471906A4/en not_active Withdrawn
- 2003-02-10 KR KR10-2004-7012208A patent/KR20040082417A/ko not_active Ceased
- 2003-02-10 BR BR0307421-8A patent/BR0307421A/pt not_active IP Right Cessation
- 2003-02-10 EA EA200401052A patent/EA007029B1/ru unknown
- 2003-02-10 CA CA002474884A patent/CA2474884A1/en not_active Abandoned
- 2003-02-10 AU AU2003215111A patent/AU2003215111A1/en not_active Abandoned
- 2003-02-10 WO PCT/US2003/003839 patent/WO2003066043A1/en not_active Ceased
- 2003-02-10 US US10/503,605 patent/US20050143467A1/en not_active Abandoned
- 2003-02-10 MX MXPA04007556A patent/MXPA04007556A/es active IP Right Grant
- 2003-02-10 CN CNB038050145A patent/CN1313089C/zh not_active Expired - Fee Related
- 2003-02-10 JP JP2003565467A patent/JP2005523270A/ja active Pending
-
2004
- 2004-08-02 IL IL163312A patent/IL163312A/en not_active IP Right Cessation
- 2004-08-13 US US10/917,525 patent/US20050106217A1/en not_active Abandoned
-
2006
- 2006-10-02 US US11/537,968 patent/US7459481B2/en not_active Expired - Fee Related
-
2008
- 2008-11-06 US US12/266,425 patent/US20090124684A1/en not_active Abandoned
- 2008-11-20 AU AU2008249144A patent/AU2008249144A1/en not_active Abandoned
-
2009
- 2009-10-20 JP JP2009241309A patent/JP2010047594A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2474884A1 (en) | 2003-08-14 |
| AU2003215111A1 (en) | 2003-09-02 |
| US20050143467A1 (en) | 2005-06-30 |
| CN1638758A (zh) | 2005-07-13 |
| KR20040082417A (ko) | 2004-09-24 |
| WO2003066043A1 (en) | 2003-08-14 |
| BR0307421A (pt) | 2004-12-28 |
| IL163312A (en) | 2011-12-29 |
| US7459481B2 (en) | 2008-12-02 |
| EP1471906A1 (en) | 2004-11-03 |
| JP2010047594A (ja) | 2010-03-04 |
| US20090124684A1 (en) | 2009-05-14 |
| AU2008249144A1 (en) | 2008-12-11 |
| CN1313089C (zh) | 2007-05-02 |
| JP2005523270A (ja) | 2005-08-04 |
| EP1471906A4 (en) | 2006-02-01 |
| US20070087037A1 (en) | 2007-04-19 |
| US20050106217A1 (en) | 2005-05-19 |
| EA200401052A1 (ru) | 2005-02-24 |
| EA007029B1 (ru) | 2006-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUT62798A (en) | Process for producing pharmaceutical composition with slimming activity | |
| IL157208A0 (en) | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical | |
| MXPA05008617A (es) | Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i. | |
| DE69735581D1 (de) | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung | |
| PT910647E (pt) | Variantes hiperactivas da dnase i humana | |
| MXPA04006051A (es) | Bifenilmetil-tiazolidindionas, analogos y su uso como activadores de ppar-gamma. | |
| ATE373082T1 (de) | Pre-adipose zelllinien | |
| MXPA04007556A (es) | Estimulacion de cpt-1 como medio para reducir peso. | |
| AU4258101A (en) | Combination therapies with vascular damaging activity | |
| CN101904946B (zh) | 一种全效茶薰天然活性脂肪抑制配方 | |
| BG104797A (en) | Use of dexmedetomi dine for sedative effect in patients in an intensive care unit | |
| NZ328874A (en) | Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders | |
| Pisani et al. | Interaction of carbamazepine‐10, 11‐epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study | |
| RU2006126980A (ru) | Увлажняющий кожу агент для перорального введения и функциональные продукты питания и напитки | |
| TW200517119A (en) | Method of treatment using interferon-tau | |
| IL151627A0 (en) | Divided dose therapies with vascular damaging activity | |
| EP1622450A4 (en) | PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE | |
| TW200501973A (en) | Method of improvement of blood circulation | |
| DE502005001398D1 (de) | Hautpflegeprodukt enthaltend Ursolsäure und Ginkgo-Extrakt | |
| RU2006110550A (ru) | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна | |
| TW200613032A (en) | Uses for augmenting bone | |
| RU2002113429A (ru) | Способ лечения псориаза | |
| JP2010285386A (ja) | 抗炎症剤 | |
| TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components | |
| RU2002129102A (ru) | Лечение разделенными дозами агентов с сосудоразрушающей активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |